Abstract:The bivalent ligand approach has been utilized not only to study the underlying mechanism of G protein-coupled receptors dimerization and/or oligomerization, but also to enhance ligand affinity and/or selectivity for potential treatment of a variety of diseases by targeting this process. Substance abuse and addiction have made both the prevention and the treatment of human immunodeficiency virus (HIV) infection more difficult to tackle. Morphine, a mu opioid receptor (MOR) agonist, can accelerate HIV infection through up-regulating the expression of the chemokine receptor CCR5, a well-known co-receptor for HIV invasion to the host cells and this has been extensively studied. Meanwhile, two research groups have described the putative MOR-CCR5 heterodimers in their independent studies. The purpose of this paper is to report the design and synthesis of a bivalent ligand to explore the biological and pharmacological process of the putative MOR-CCR5 dimerization phenomenon. The developed bivalent ligand thus contains two distinct pharmacophores linked through a spacer; ideally one of which will interact with the MOR and the other with the CCR5. Naltrexone and Maraviroc were selected as the pharmacophores to generate such a bivalent probe. The overall reaction route to prepare this bivalent ligand was convergent and efficient, and involved sixteen steps with moderate to good yields. The preliminary biological characterization showed that the bivalent compound 1 retained the pharmacological characteristics of both pharmacophores towards the MOR and the CCR5 respectively with relatively lower binding affinity, which tentatively validated our original molecular design.

Design, Synthesis, And Evaluation Of Biotinylated Opioid Derivatives As Novel Probes To Study Opioid Pharmacology

Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor Modulators

Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.

Photo‐affinity and Metabolic Labeling Probes Based on the Opioid Alkaloids

Design, Syntheses, and Pharmacological Characterization of 17-Cyclopropylmethyl-3,14 Beta-Dihydroxy-4,5 Alpha-Epoxy-6 Alpha-(Isoquinoline-3 '-Carboxamido)morphinan Analogues As Opioid Receptor Ligands

Design, Synthesis, and Biological Evaluation of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan Derivatives As Peripheral Selective Μ Opioid Receptor Agents.

Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives As Μ/κ Opioid Receptor Dual Selective Ligands.

Design and Synthesis of a Bivalent Probe Targeting the Putative Mu Opioid Receptor and Chemokine Receptor CXCR4 Heterodimer

14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.

Structure activity relationship studies of 6α- and 6β-indolylacetamidonaltrexamine derivatives as bitopic mu opioid receptor modulators and elaboration of the 'message-address concept' to comprehend their functional conversion.

Design, synthesis, and biological evaluation of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as μ opioid receptor selective Antagonists

Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.

Design and Synthesis of a Bivalent Ligand to Explore the Putative Heterodimerization of the Mu Opioid Receptor and the Chemokine Receptor CCR5.

Synthesis and Evaluation of Κ-Opioid Receptor Agonistic Activity and Antinociceptive Effect of Novel Morphine Analogues, 7Α-Phenyl-6α,14α-endo-etheno-tetrahydrothebaine with Substituted O-, M- and P-Amino Group

Synthesis and SAR Study of Opioid Receptor Ligands: Mono‐ and Bis‐Indolomorphinans

Study on the Activation of the Opioid Receptors by a Set of Morphine Derivatives in a Well-Defined Assay System

Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics for affinity and function.

Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.

Binding Mode Analyses of NAP Derivatives As Mu Opioid Receptor Selective Ligands Through Docking Studies and Molecular Dynamics Simulation

Synthesis and Structure-Activity Relationships of 5-Aryl-14-alkoxypyridomorphinans: Identification of a Opioid Receptor Agonist/ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects

Computer‐Aided Design of Opioid Receptors Dual Action Ligands with Mitigated Side Effects As a Potential New Avenue for Analgesic and Substance Abuse Treatment